Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143796 |
| CAS No | NA |
| Mol.F. | C8H7F3N4O5S2 |
| Mol.Wt. | 360.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143797 |
| CAS No | NA |
| Mol.F. | C15H16N2O4 |
| Mol.Wt. | 288.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143798 |
| CAS No | NA |
| Mol.F. | C15H18N2O4 |
| Mol.Wt. | 290.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143799 |
| CAS No | 2639422-25-4 |
| Mol.F. | C10H19N3O |
| Mol.Wt. | 197.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143800 |
| CAS No | NA |
| Mol.F. | C8H14N2O5 |
| Mol.Wt. | 218.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143801 |
| CAS No | NA |
| Mol.F. | C8H15N3O4 |
| Mol.Wt. | 217.2 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143802 |
| CAS No | NA |
| Mol.F. | C8H14ClN3O3 |
| Mol.Wt. | 235.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143803 |
| CAS No | NA |
| Mol.F. | C17H9D8FN4O5 |
| Mol.Wt. | 384.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143804 |
| CAS No | NA |
| Mol.F. | C34H39N7O7 |
| Mol.Wt. | 657.7 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143805 |
| CAS No | NA |
| Mol.F. | C12H12D5N3O2 |
| Mol.Wt. | 240.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143806 |
| CAS No | NA |
| Mol.F. | C10H19D4N3O3 |
| Mol.Wt. | 237.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143807 |
| CAS No | NA |
| Mol.F. | C10H18D4N4O4 |
| Mol.Wt. | 266.3 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143808 |
| CAS No | NA |
| Mol.F. | C10H22N215N2O4 |
| Mol.Wt. | 264.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143809 |
| CAS No | NA |
| Mol.F. | C10H23N215NO3 |
| Mol.Wt. | 234.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143810 |
| CAS No | NA |
| Mol.F. | C17H14D3F3N2O2 |
| Mol.Wt. | 341.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143811 |
| CAS No | NA |
| Mol.F. | C17H12D5F3N2O2 |
| Mol.Wt. | 343.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |